Phase 1b Study of Pirtobrutinib, Plerixafor, and Lisocabtagene Maraleucel in relapsed/refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and mantle cell lymphoma
Key Points
Treatment with pirtobrutinib shows encouraging results for patients with lymphoma, enhancing remission rates.
A combination of pirtobrutinib, plerixafor, and lisocabtagene maraleucel was utilized to target resistant cases.
This observational analysis focused on relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.
Further clinical trials are needed to validate these findings and improve treatment options for lymphomas.
Phase 1b Study of Pirtobrutinib, Plerixafor, and Lisocabtagene Maraleucel in relapsed/refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and mantle cell lymphoma | Synapse